Search hospitals > California > Ontario
Kaiser Permanente-Ontario
Claim this profileOntario, California 91761
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Colorectal Cancer
71 reported clinical trials
10 medical researchers
Summary
Kaiser Permanente-Ontario is a medical facility located in Ontario, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Kaiser Permanente-Ontario is involved with conducting 71 clinical trials across 219 conditions. There are 10 research doctors associated with this hospital, such as Gary L. Buchschacher, Helen H. Moon, Eric C. McGary, and Ashraf R. Aziz.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
PR positive
Top PIs
Gary L. BuchschacherKaiser Permanente-Anaheim6 years of reported clinical research
Studies Colorectal Cancer
Studies Cancer
13 reported clinical trials
34 drugs studied
Helen H. MoonKaiser Permanente-Riverside7 years of reported clinical research
Studies Cancer
Studies Bladder Cancer
13 reported clinical trials
23 drugs studied
Eric C. McGaryKaiser Permanente-Fontana9 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
10 reported clinical trials
18 drugs studied
Ashraf R. AzizKaiser Permanente-Baldwin Park5 years of reported clinical research
Studies Lymphoma
Studies Leukemia
11 reported clinical trials
31 drugs studied
Clinical Trials running at Kaiser Permanente-Ontario
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Prostate Cancer
Diffuse Large B-Cell Lymphoma
Cancer
Squamous Cell Carcinoma
Lymphoma
Colorectal Cancer
Small Intestinal Adenocarcinoma
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Kaiser Permanente-Ontario?
Kaiser Permanente-Ontario is a medical facility located in Ontario, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Kaiser Permanente-Ontario is involved with conducting 71 clinical trials across 219 conditions. There are 10 research doctors associated with this hospital, such as Gary L. Buchschacher, Helen H. Moon, Eric C. McGary, and Ashraf R. Aziz.